A5036091074- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Cancer Research and Treatments
- Cancer Treatment and Pharmacology
- Epigenetics and DNA Methylation
- Neuroendocrine Tumor Research Advances
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- Gastric Cancer Management and Outcomes
- Cancer, Hypoxia, and Metabolism
- DNA Repair Mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Synthesis and biological activity
- Lymphoma Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
UC Davis Comprehensive Cancer Center
2016-2025
University of California, Davis
2016-2025
University of California Davis Medical Center
2013-2024
Nizam's Institute of Medical Sciences
2008-2023
Jeroen Bosch Ziekenhuis
2008-2023
Heidelberg University
2005-2023
University Hospital Heidelberg
2006-2023
University of Hawaii Cancer Center
2022
AstraZeneca (Brazil)
2019-2021
Merck (Germany)
2019-2021
Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies pemetrexed platinum compounds have also shown activity in this setting. Patients and Methods This noninferiority, phase III, randomized study compared the overall survival between arms using fixed margin method (hazard ratio [HR] < 1.176) 1,725 chemotherapy-naive patients with stage IIIB or IV NSCLC an Eastern Cooperative Oncology Group...
We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer.We randomly assigned stage IB or II cancer observation. The primary end point was survival; principal secondary points were recurrence-free and the toxicity safety of regimen.A total 482 underwent randomization (242 patients) observation (240); 45 percent had pathological disease 55 II, all an Eastern Cooperative...
PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this III trial was conducted chemotherapy for patients with advanced non–small-cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy. PATIENTS AND METHODS: A total 373 were randomized to receive either 100 mg/m 2 (D100) or 75 (D75) versus a control regimen vinorelbine ifosfamide (V/I). The three treatment groups well-balanced key patient characteristics. RESULTS: Overall response rates...
PURPOSE: This randomized trial was designed to determine whether paclitaxel plus carboplatin (PC) offered a survival advantage over vinorelbine cisplatin (VC) for patients with advanced non–small-cell lung cancer. Secondary objectives were compare toxicity, tolerability, quality of life (QOL), and resource utilization. PATIENTS AND METHODS: Two hundred two received VC (vinorelbine 25 mg/m 2 /wk 100 /d, day 1 every 28 days) 206 PC (paclitaxel 225 3 hours area under the curve 6, 21 days)....
PURPOSE To assess the feasibility of concurrent chemotherapy and irradiation (chemoRT) followed by surgery in locally advanced non-small-cell lung cancer (NSCLC) a cooperative group setting, to estimate response, resection rates, relapse patterns, survival for stage subsets IIIA(N2) versus IIIB. PATIENTS AND METHODS Biopsy proof either positive N2 nodes (IIIAN2) or N3 T4 primary lesions (IIIB) was required. Induction two cycles cisplatin etoposide plus chest RT 45 Gy. Resection attempted if...
Purpose Bronchioloalveolar carcinoma (BAC) and adenocarcinomas with BAC features seem to be increasing in incidence, particularly younger, never-smoking women. Epidermal growth factor receptor (EGFR) inhibitors demonstrated response rates of 20% 30% patients advanced subtypes, but selection methods for patient therapy are not established. Patients Methods EGFR HER2 gene copy numbers were assessed by fluorescence situ hybridization (FISH) 81 treated gefitinib 500 mg/d (Southwest Oncology...
PURPOSE Cisplatin has played a major role in the treatment of non-small-cell lung cancer (NSCLC). This randomized trial was performed by Southwest Oncology Group (SWOG) to determine whether combination vinorelbine and cisplatin any advantage with regard response rate, survival, time failure over single-agent patients advanced NSCLC. METHODS Between October 1993 April 1995, 432 stage NSCLC were receive arm I (cisplatin 100 mg/m2 every 4 weeks) or II weeks 25 weekly). All chemotherapy-naive,...
PURPOSE: Well-conducted cancer clinical trials are essential for improving patient outcomes. Unfortunately, only 3% of new patients participate in trials. Barriers to accrual must be identified and overcome increase participation. MATERIALS AND METHODS: We prospectively tracked factors that potentially affected into at the University California Davis Cancer Center. Oncologists seeing outpatients were asked complete questionnaires regarding characteristics physician’s decision-making on...
Purpose Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients advanced non–small-cell lung cancer (NSCLC). Thus, was an ideal agent to evaluate a maintenance setting stage III disease. Patients Methods Untreated NSCLC, performance score of 0 1, adequate organ function were eligible. All received cisplatin 50 mg/m 2 on days 1 8 plus etoposide 5, every 28 for two cycles concurrent thoracic radiation (1.8- 2-Gy fractions per day; total dose, 61 Gy)...
Purpose Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors VEGF suppress tumor OC models. Metronomic chemotherapy, defined as frequent administration low doses cytotoxic suppresses growth, possibly by inhibiting angiogenesis. A phase II trial was conducted to evaluate antitumor activity and adverse effects bevacizumab metronomic oral cyclophosphamide women with recurrent OC. Patients Methods measurable disease prior treatment a...
Irinotecan plus cisplatin (IP) improved survival over etoposide (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) outcomes, we conducted a large randomized trial identical design to North American E-SCLC.Patients were randomly assigned IP (irinotecan 60 mg/m(2) on days 1, 8, 15; day every 4 weeks) or EP (etoposide 100 1 through 3; 80 3 weeks). Blood specimens for...
Purpose Although current treatment options for metastatic non–small-cell lung cancer (NSCLC) rely on cisplatin-based chemotherapy, individualized approaches to therapy may improve response or reduce unnecessary toxicity. Excision repair cross-complementing 1 (ERCC1) has been associated with cisplatin resistance. We hypothesized that assigning based pretreatment ERCC1 mRNA levels would response. Patients and Methods From August 2001 October 2005, 444 stage IV NSCLC patients were enrolled. RNA...
Purpose The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, versus etoposide-cisplatin TRT nonpemetrexed doublet therapy. Patients Methods with stage IIIA/B unresectable nonsquamous non–small-cell lung cancer randomly received (1:1) pemetrexed 500 mg/m 2 cisplatin 75 intravenously every 3 weeks for three cycles plus (60 to 66 Gy) four (arm A), or standard etoposide 50...
Purpose Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non–small-cell lung cancer (NSCLC). Long-term follow-up important to document persistent benefit late toxicity. We report here updated overall survival (OS) disease-specific (DSS) data. Patients Methods with IB (T2N0, n = 219) or (T1-2N1, 263) NSCLC were randomly assigned receive 4 cycles of vinorelbine/cisplatin observation. All efficacy analyses performed on...